Featured Research

from universities, journals, and other organizations

Only small number of symptomatic side effects reported in those taking statins are actually attributable to statins, study finds

Date:
March 13, 2014
Source:
European Society of Cardiology (ESC)
Summary:
Only a small number of symptomatic side effects reported in those taking statins are actually attributable to statins, according to large meta-analysis of prevention trials, and investigators of a new study are calling on drug regulators to provide clear evidence to patients on claims of drug side effects.

Blood pressure and cholesterol medicines (stock photo). "Patients and doctors need clear reliable information about benefits and risks to make informed decisions," the authors write, adding that those reporting symptomatic side effects during statin therapy need reliable confirmation that a symptom is truly caused by the drug.
Credit: © David Watkins / Fotolia

At a time when the wider prescription of statins is under renewed public scrutiny, a substantial analysis of placebo-controlled randomized trials of statins has found that only a small minority of side effects reported by those taking the cholesterol-lowering drugs are actually attributable to them. Almost all the side effects reported in these trials "occurred anyway when patients were administered placebo," say the investigators.

Related Articles


The study, a meta-analysis involving more than 80,000 patients and reported today in the European Journal of Preventive Cardiology, was performed without funding from any agency in the public, commercial or not-for-profit sectors.(1)

Explaining the need for such a study, the authors note that evaluation of the efficacy of statins is always based on the evidence of randomised controlled trials (RCTs) against placebo, while the evaluation of side effects is not. Adverse events listed for statins come from many sources, they note, including observational studies, in which most are unable to differentiate between events caused by the drug or caused by chance.

"Patients and doctors need clear reliable information about benefits and risks to make informed decisions," they write, adding that those reporting symptomatic side effects during statin therapy need reliable confirmation that a symptom is truly caused by the drug.

This study analysed the prevalence of side effects in 29 eligible RCTs performed for the primary (46,262 participants) and secondary (37,618) prevention of cardiovascular disease. Data on all adverse effects, cardiovascular events and death were recorded in both the treatment and control (placebo) arms of the studies. Using a statistical model, the investigators calculated the increase in risk for each side effect in the statin and placebo arms.

Among a long list of side effects assessed -- which included nausea, renal disorder, myopathy and rhabdomyolysis (muscle breakdown), muscle ache, insomnia, fatigue, and gastrointestinal disturbance -- only the risk of new onset diabetes mellitus was increased by statin therapy.

In the 14 primary prevention trials, randomisation to statins rather than placebo significantly increased the prevalence of diabetes by 0.5% (and similarly reduced mortality rate by 0.5%). And across both primary and secondary prevention trials, the rate of developing diabetes with statins was 3%, against 2.4% with placebo, thus indicating that around one in five of new cases of diabetes was actually caused by statins.

Otherwise, the authors report, the many side effects commonly attributed to statins (notably myopathy, fatigue, muscle aches, and rhabdomyolysis) were no more common in the statin arms of these RCTs than in the placebo arms.

Overall, the study found serious adverse effects in 14.6% of patients receiving statins and 14.9% given placebo in the primary prevention trials, and in 9.9% of those on statins and 11.2% on placebo in the secondary prevention trials. Similarly, comparable numbers of patients withdrew from the trials because of symptomatic adverse events (around 12-15%).

In their bid to provide doctors with a clear estimate of the risk of side effects genuinely attributable to statins, the investigators have calculated a "clear, understandable metric for everyday clinical use" -- the proportion of side effects not attributable to their pharmacological action, or PSN.

Thus, in the diabetes risk noted above, 20% (0.6/3.0) of all new diabetes diagnoses on statins were directly attributable to the drugs, giving a PSN of 80.

Despite the findings, the authors acknowledge that many real-world patients do report symptoms with statins -- which of course contrasts markedly with their results. In explaining this, the study's first author, Dr Judith Finegold from the National Heart and Lung Institute in London, says: "We clearly found that many patients in these trials -- whose patients are usually well motivated volunteers who didn't know if they were getting a real or placebo tablet -- that many did report side effects while taking placebo. In the general population, where patients are being prescribed a statin for an asymptomatic condition, why would it be surprising that even higher rates of side effects are reported?

"Most people in the general population, if you repeatedly ask them a detailed questionnaire, will not feel perfectly well in every way on every day. Why should they suddenly feel well when taking a tablet after being warned of possible adverse effects?"

Asked if the study results add weight to the case for the wider prescription of statins, Dr Finegold said: " No, we think that our results will help improve the patient-doctor consultation. We believe that patients should be empowered to make their own decisions, but we must first make sure they have top quality unbiased information. This is why we call on drug regulators to highlight in the long lists of side effects those few whose rate is incrementally greater than that experienced with a dummy tablet."


Story Source:

The above story is based on materials provided by European Society of Cardiology (ESC). Note: Materials may be edited for content and length.


Journal Reference:

  1. J. A. Finegold, C. H. Manisty, B. Goldacre, A. J. Barron, D. P. Francis. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. European Journal of Preventive Cardiology, 2014; DOI: 10.1177/2047487314525531

Cite This Page:

European Society of Cardiology (ESC). "Only small number of symptomatic side effects reported in those taking statins are actually attributable to statins, study finds." ScienceDaily. ScienceDaily, 13 March 2014. <www.sciencedaily.com/releases/2014/03/140313092443.htm>.
European Society of Cardiology (ESC). (2014, March 13). Only small number of symptomatic side effects reported in those taking statins are actually attributable to statins, study finds. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2014/03/140313092443.htm
European Society of Cardiology (ESC). "Only small number of symptomatic side effects reported in those taking statins are actually attributable to statins, study finds." ScienceDaily. www.sciencedaily.com/releases/2014/03/140313092443.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins